Owa T - Search Results

1

Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Scozzafava A, et al. Among authors: owa t. Curr Med Chem. 2003 Jun;10(11):925-53. doi: 10.2174/0929867033457647. Curr Med Chem. 2003. PMID: 12678681 Review.

2

Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.

Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT. Abbate F, et al. Among authors: owa t. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. doi: 10.1016/j.bmcl.2003.09.062. Bioorg Med Chem Lett. 2004. PMID: 14684331

3

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.

Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K. Owa T, et al. J Med Chem. 1999 Sep 23;42(19):3789-99. doi: 10.1021/jm9902638. J Med Chem. 1999. PMID: 10508428

4

Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.

Owa T, Yokoi A, Yamazaki K, Yoshimatsu K, Yamori T, Nagasu T. Owa T, et al. J Med Chem. 2002 Oct 24;45(22):4913-22. doi: 10.1021/jm0201060. J Med Chem. 2002. PMID: 12383017

5

Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.

Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Owa T, et al. Curr Med Chem. 2001 Oct;8(12):1487-503. doi: 10.2174/0929867013371996. Curr Med Chem. 2001. PMID: 11562278 Review.

6

Sulfonamide drugs binding to the colchicine site of tubulin: thermodynamic analysis of the drug-tubulin interactions by isothermal titration calorimetry.

Banerjee M, Poddar A, Mitra G, Surolia A, Owa T, Bhattacharyya B. Banerjee M, et al. Among authors: owa t. J Med Chem. 2005 Jan 27;48(2):547-55. doi: 10.1021/jm0494974. J Med Chem. 2005. PMID: 15658868

7

Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.

Owa T, Yoshino H, Okauchi T, Okabe T, Ozawa Y, Hata Sugi N, Yoshimatsu K, Nagasu T, Koyanagi N, Kitoh K. Owa T, et al. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2097-100. doi: 10.1016/s0960-894x(02)00376-1. Bioorg Med Chem Lett. 2002. PMID: 12127512

8

Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, Kamiyama H, Takahashi K, Kotake Y, Uesugi M, Yokoi A, Inoue A, Yoshida T, Mabuchi M, Tanaka A, Owa T. Uehara T, et al. Among authors: owa t. Nat Chem Biol. 2017 Jun;13(6):675-680. doi: 10.1038/nchembio.2363. Epub 2017 Apr 24. Nat Chem Biol. 2017. PMID: 28437394

9

A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors.

Owa T, Okauchi T, Yoshimatsu K, Sugi NH, Ozawa Y, Nagasu T, Koyanagi N, Okabe T, Kitoh K, Yoshino H. Owa T, et al. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1223-6. doi: 10.1016/s0960-894x(00)00219-5. Bioorg Med Chem Lett. 2000. PMID: 10866386

10

Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.

Charupant K, Daikuhara N, Saito E, Amnuoypol S, Suwanborirux K, Owa T, Saito N. Charupant K, et al. Among authors: owa t. Bioorg Med Chem. 2009 Jul 1;17(13):4548-58. doi: 10.1016/j.bmc.2009.05.009. Epub 2009 May 8. Bioorg Med Chem. 2009. PMID: 19457672

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page